Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY webinars

Accelerating Precision Medicine with Rapid Front-Line NGS-April 30, 2026

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC, discusses how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Multicenter Evaluation of Next-Day CGP Using the Oncomine™ Comprehensive Assay Plus on the Genexus™ System-April 28, 2026

Webinar presenters Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Morten Grauslund, PhD,Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark, discuss how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Automated and integrated genomic profiling of hematologic malignancies-March 5, 2026

Join David Gonzalez, PhD, FRCPath, one of the leading experts in the EuroClonality-NGS working group of the Euroclonality consortium, dedicated to advancing standardized diagnostics in hematology-oncology, to learn:

• How EuroClonality-NDC and Myeloid-NDC NGS Workflows are utilized in advancing the future of diagnostics, prognostics, and targeted therapies.

• How these revolutionary assays provide comprehensive genomic data that reveals mutations, structural variations, and clonal evolution patterns with remarkable resolution, enabling clinical researchers to delve deeper into the genomic landscape of hematological malignancies.

From Cough to Critical: The Role of Syndromic Respiratory Testing Across the Care Continuum-January 21, 2026


Webinar presenters Shyam M. Sivasankar, MD, FAAP, FACEP, Associate Trauma Medical Director & Assistant Professor, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, and Dan Feinstein, MD, FACP, Director of Pulmonary Critical Care Medicine, Triad Region; System-wide Director, TeleICU & Co-Director, Sepsis, Novant Health, team up for this session bringing together two physicians—one representing inpatient and critical care from a large health system, and the other offering a perspective on urgent and near-patient care—to share how syndromic polymerase chain reaction (PCR) testing informs real-world patient management.

A scan of studies on HER2-low breast cancer scoring

January 2024—Much has been said and written about scoring HER2-low breast cancer, and it has its difficulties. But there are steps and tools to support scoring, and Savitri Krishnamurthy, MD, last fall shined a light on them and several HER2-low breast cancer-related studies.

Fast or comprehensive? Lab offers both for NSCLC

October 2023—For molecular testing in oncology, the choice is often fast or slow. PCR-based platforms are rapid, and comprehensive genomic profiling by next-generation sequencing is slower, and each has its pros and cons.

No time to wait: How rapid NGS changed cancer care

November 2022—Rapid next-generation sequencing in a community hospital setting, performed by histotechnologists and interpreted by anatomic pathologists, is possible and paying off, and it “makes the pathologist a much more meaningful part of the precision oncology team,” says Brandon Sheffield, MD, of the Department of Laboratory Medicine, William Osler Health System, Brampton/Etobicoke, Ontario. “It has changed practice at our hospitals,” he says.

Scoring HER2 expression across the full spectrum

October 2022—HER2-low breast cancers are now of greater clinical interest, given Enhertu’s recent approval for use in treating such cancers. How to achieve accurate and reproducible results in scoring HER2-low tumors was at the center of a CAP TODAY webinar on new perspectives on the full spectrum of HER2 expression in breast cancer.

Close-up on HER2 alterations in advanced NSCLC

August 2022—HER2 is a known oncogenic driver and emerging biomarker in non-small cell lung cancer, and while the therapeutic implication is not yet fully known in NSCLC, “we need to pay attention to it,” said Fred R. Hirsch, MD, PhD, executive director of the Mount Sinai Center for Thoracic Oncology and associate director, Tisch Cancer Institute, in a CAP TODAY webinar sponsored by Daiichi-Sankyo and AstraZeneca.

MARKETPLACE

TRENDING